Latera RCT – Latera® Absorbable Nasal Implant vs. Sham Control for 
Lateral Nasal Valve Collapse
Device:
 Latera™  
Protocol Number : CP04 
Version: 3.0 
23 March  2018 
Sponsor  
S
pirox, Inc. 
595 Penobscot Drive 
Redwood City, CA  94063 USA  
CONFIDENTIALITY STATEMENT  
This Clinical Investigation Plan and all attachments are considered confidential information. The contents 
must  not be disclosed, unless authorized in writing by Spirox, Inc., except that this document may be 
disclosed to the appropriate Institutional Review Board (IRB) or duly authorized representative of the U.S. 
Food and Drug Administration (FDA) with similar requests for maintenance of confidentiality. All data 
and study results are similarly subjected to the same disclosure restrictions as the investigational plan, as 
stated above. All copies of this investigational device exemption  remain the property of Spirox, Inc.  

Spirox, Inc. 
LATERA RCT  Version 3.0 
23 March 2018  
  
 
LATERA RCT  Page 2 CONFIDENTIAL  TABLE OF CONTENTS 
Table of Contents  ........................................................................................................................................ 2 
Summary of Changes  .................................................................................................................................. 6 
Statement of Compliance  ........................................................................................................................... 7 
Investigator Signature Page  ....................................................................................................................... 8 
Synopsis  ........................................................................................................................................................ 9 
1. Introduction  ....................................................................................................................................... 14 
1.1. Background on Nasal Valve Collapse ........................................................................................... 14 
1.2. Prior Investigations  ........................................................................................................................ 14 
1.3. Current Study: The Latera Randomized Controlled Trial .............................................................. 17 
2. Study Device  ...................................................................................................................................... 17 
2.1. Indication for Use  .......................................................................................................................... 18 
2.2. Manufacturer and Study Sponsor ................................................................................................... 18 
2.3. Clearance Status  ............................................................................................................................. 18 
2.4. Model Numbers ............................................................................................................................. 18 
2.5. Device Description ......................................................................................................................... 18 
3. Study Objectives and Endpoints  ...................................................................................................... 20 
3.1. Study Objectives  ............................................................................................................................ 20 
3.2. Primary Endpoint ........................................................................................................................... 20 
3.3. Secondary Endpoints ..................................................................................................................... 20 
4. Study Population  ............................................................................................................................... 20 
4.1. Patient Eligibility  ........................................................................................................................... 21 
4.2. Patient Screening and Informed Consent ....................................................................................... 22 
4.3. Subject Disposition and Flow Chart .............................................................................................. 22 
4.4. Withdrawals and Loss to Follow-up .............................................................................................. 23 
5. Study Procedures and Follow -up E valuations ................................................................................ 24 
5.1. Screening/Baseline Assessmen t ..................................................................................................... 24 
5.2. Treatment Visit  .............................................................................................................................. 25 
5.3. Follow- Up Assessments ................................................................................................................. 28 
5.4. Retrievals and Re- Implantation  ..................................................................................................... 31 
Spirox, Inc. 
LATERA RCT  Version 3.0 
23 March 2018  
LATERA RCT  Page 3 CONFIDENTIAL  6. Statistics and Data Analysis ............................................................................................................. 32 
6.1. Hypothesis ..................................................................................................................................... 32 
6.2. Study Populations .......................................................................................................................... 32 
6.3. Unblinding and Crossover Subjects ............................................................................................... 33 
6.4. Sample Size  .................................................................................................................................... 33 
6.5. Missing Data  .................................................................................................................................. 33 
6.6. Demographics and Baseline Characteristics  .................................................................................. 34 
6.7. Changes to Planned Analyses  ........................................................................................................ 34 
6.8. Interim Analyses ............................................................................................................................ 34 
7. Study Management Considerations  ................................................................................................. 34 
7.1. Data Management: Collection of Clinical Data  ............................................................................. 34 
7.2. Protocol Amendments .................................................................................................................... 35 
7.3. Protocol Deviations ........................................................................................................................ 35 
7.4. Information to Study Personnel ..................................................................................................... 35 
8. Risk -Benefit Analysis  ........................................................................................................................ 35 
8.1. Risks to the Subjects  ...................................................................................................................... 35 
8.2. Risk Mitigation  .............................................................................................................................. 37 
8.3. Benefit to Subjects  ......................................................................................................................... 37 
8.4. Study Justification .......................................................................................................................... 37 
9. Assessments of Safety  ........................................................................................................................ 38 
9.1. Defining Adverse Events  ............................................................................................................... 38 
9.2. Reporting of Adverse Events ......................................................................................................... 39 
9.3. Medical Monitor  ............................................................................................................................ 39 
9.4. Data Monitoring Committee  .......................................................................................................... 40 
10. Study A
dministration ........................................................................................................................ 40 
10.1.  Site Initiation and Study Monitoring ............................................................................................. 40 
10.2.  Study Termination ......................................................................................................................... 40 
10.3.  Data Handling and Recordkeeping  ................................................................................................ 40 
11. Ethics .................................................................................................................................................. 41 
11.1.  Informed Consent .......................................................................................................................... 41 
11.2.  Institutional Review Board (IRB) .................................................................................................. 42 
Spirox, Inc. 
LATERA RCT  Version 3.0 
23 March 2018  
LATERA RCT  Page 4 CONFIDENTIAL  12. Investigators and Responsibilities  ................................................................................................... 43 
12.1.  Participating Institutions and Investigators  .................................................................................... 43 
12.2.  Agreements .................................................................................................................................... 43 
12.3.  Investigator Responsibilities  .......................................................................................................... 43 
13. Data Security and Scientific Integrity  ............................................................................................. 44 
13.1.  Access to Data  ............................................................................................................................... 44 
13.2.  Security and Confidentiality .......................................................................................................... 44 
14. Publications  ........................................................................................................................................ 44 
15. Abbreviations  .................................................................................................................................... 45 
16. References  .......................................................................................................................................... 47 
ATTACHMENT A. Protocol Approval Page  ......................................................................................... 49 
ATTACHMENT B.  Declaration of Helsinki  ......................................................................................... 50 
ATTACHMENT C.  Informed Consent Form  ....................................................................................... 54 
ATTACHMENT D.  Latera Instructions For Use  ................................................................................. 55 
ATTACHMENT E.  Financial Disclosure Form  .................................................................................... 56 
ATTACHMENT F.  Case Report Forms and Patient Report ed Outcomes  ........................................ 57 
ATTACHMENT G. Patient and Site Brochure  ..................................................................................... 58 
Spirox, Inc. 
LATERA RCT  Version 3.0 
23 March 2018  
  
 
LATERA RCT  Page 5 CONFIDENTIAL  LISTING OF TABLES  
Table 1. Outcome in the three Latera studies  .............................................................................................. 17 
Table 2. Schedule of Study Activities  ......................................................................................................... 28 
Table 3. Planned analyses  ........................................................................................................................... 34 
Table 4. Abbreviations  ................................................................................................................................ 45 
 
 
LISTING OF FIGURES  
Figure 1. 24-Month Results from Spirox First Study; Percent Responders (NOSE Score) ........................ 16 
Figure 2: LATERA Absorbable Nasal Implant and Packaging  .................................................................. 19 
Figure 3. Delivery device and implant positioning guide. .......................................................................... 19 
Figure 4. Flow of subjects in the trial and definitions of the ITT, mITT and PP populations. ................... 23 
  
Spirox, Inc. 
LATERA RCT  Version 3.0 
23 March 2018  
  
 
LATERA RCT  Page 6 CONFIDENTIAL  SUMMARY OF CHANGES 
 
 
Relevant 
Section(s)  Summary of Revisions  Rationale  
Synopsis , 
Exclusion 
Criteria, p.12    
and 
4.1 Exclusion 
#13, p22. 
 
Section 5.3, Page 
29 Exclusion criteria for OSA and CPAP 
users  changed from 4 weeks to 
approximately 2 weeks of post -
procedure management of CPAP mask use.   
 
 
Removal of “7 days”. Better reflects current practice and 
variety of masks in use throughout 
U.S. 
 
 
 
 Administrative change to remove 
inconsistency in study plan, no 
change to study version  
Version 3.0  
 Add “X” to Table 2 – Schedule of Study 
Activities for consistency across all sections of protocol. 
 
 
 
 
 
Widened windows  from ±14 days to ± 
30 days  for 12Month, 18Month and 24 
Month visits  to support site scheduling 
needs.   
 NCT Identification number added Administrative change to clarify data 
collected at 7 Day Visit.  
Administrative change to clarify 
pregnancy test requirements as part 
of screening for patient availability.  Allows consistency with Eligibility 
and follow up and analysis plan. 
 
Increase flexibility to assure 
likelihood of follow up.  No impact 
on primary endpoint which uses 
3Month assessments.  
 
NCT Identification number now 
available.  
 
 
  
Spirox, Inc. 
LATERA RCT  Version 3.0 
23 March 2018  
  
 
LATERA RCT  Page 7 CONFIDENTIAL  STATEMENT OF COMPLIANCE 
The trial will be carried out in accordance with International Conference on Harmonisation Good Clinical 
Practice (ICH GCP) and the United States (US) Code of Federal Regulations (CFR) applicable to clinical 
studies (45 CFR Part 46, 21 CFR Part 50, 21 CFR Part 56, and 21 CFR Part 812). 
This Clinical Investigational Plan (CIP), informed consent forms (ICF) , recruitment materials, and all 
participant materials will be submitted to the Institutional Review Board (IRB) for review and approval. 
Approval of the CIP  and the ICF must be obtained before any subject  is enrolled. Any amendment to the 
CIP will require review and approval by the IRB before the changes are implemented to the study.  In 
addition, all changes to the ICF will be IRB -approved and a determination will be made regarding whether 
a new consent needs to be obtained from subjects who previously provided consent . 
  
Spirox, Inc. 
LATERA RCT  Version 3.0 
23 March 2018  
LATERA RCT  Page 8 CONFIDENTIAL  INVESTIGATOR SIGNATURE PAGE 
Investigator Name  Title  
Site Name  Site Number  
I have 
read the protocol and agree that it contains all necessary details for carrying out this study. I will 
conduct the study as outlined therein.  
I agree to keep records on all subject information (e. g., source documents  and informed consent forms ), 
device shipments and return forms, and all other information collected during the study, in accordance with 
local and national regulations.  
Investigator Signature  Date  
Spirox, Inc. 
LATERA RCT  Version 3.0 
23 March 2018  
LATERA RCT  Page 9 CONFIDENTIAL  SYNOPSIS 
Study Title  Latera RCT – Latera® Absorbable Nasal Implant  vs. Sham Control 
for Lateral Nasal Valve Collapse  
Spirox Protocol  Number  CP04 
Investigational Device  Spirox Latera Absorbable Nasal Implant  
ClinicalTrials.gov Identifier  NCT  03400787 
Sponsor  Spirox, Inc.  
595 Penobscot Drive  
Redwood City, CA  94063 USA  
Study Purpose  To evaluate the Latera Absorbable Nasal Implant (Latera Implant)  
Implant  versus Sham Control  in subjects with nasal valve collapse 
due to or primarily due to insufficient cartilaginous support of the 
lateral nasal wall  
Objective  The primary objective of the LATERA RCT is to demonstrate the 
superiority of the Latera Implant  to improve nasal breathing, 
compared with a Sham Control treatment . 
Phase of Study  Post-market  
Study Design Randomized  (1:1) , sham -controlled, single -blind, multicenter post-
market trial using an adaptive trial design 
Investigational Sites  Up to 15 investigational sites in the United States, in  office -based 
locations with investigators experienced in standard nasal 
interventions  for airway obstructions  and the use of the Latera 
Implant  
Study Population The Adaptive Design allow s for enrollment of up to 150 subjects 
with nasal airway obstruction due to or primarily due to nasal valve 
collapse .  
Study Duration  Subjects will be followed for a total of 24  to 27  months  after 
enrollment, Latera Implant and Sham Control, respectively.   
Overall  study duration, enrollment and follow up, i s expected to be 
approximately 4 years.  
Treatment Arms  Latera Treatment Arm 
Subjects in t he active treatment arm will receive the Latera Implant , 
a PLLA -PDLA copolymer , delivered to the region of the lateral 
nasal wall cartilages to provide support.  It is placed using standard, minimally invasive techniques and is absorbed over a  period of 
approximately 18 months . 
Spirox, Inc. 
LATERA RCT  Version 3.0 
23 March 2018  
LATERA RCT  Page 10 CONFIDENTIAL  Sham Control  Arm  
Subjects in the Sham Control arm will undergo the same 
preoperative assessments as those in the Latera Treatment  arm up to 
and including anesthesia for the implant  and cannula insertion  into 
the nasal lateral wall , however, no implant will be placed. 
Randomization to the Sham Control Arm  will be assessed by the 
independent Data Monitoring Committee ( DMC ) at each interim 
analysis time point.  If the pre -determined efficacy , safety or 
operational  criteria  are met , randomization may be terminated.     
Crossover Subjects 
Subjects will be unblinded after the 3-month assessment is 
complete .  For subject s in the Sham Control  arm, the subject will be 
treated  with the Latera Implant  if they still meet all eligibility 
criteria . The subject’s data will continue to be recorded thereafter  
through 24 months  post-implant .  If the subject does not meet the 
eligibility criteria, he/she will exit the study.    
Primary Endpoint  The primary endpoint of the study is the Responder Rate , assessed 3 
months post-procedure in  the per protocol population of the Latera 
and Sham arms.  
Responder Rate  is defined as the proportion of subjects with at least 
one (1) NOSE class improvement or at least 20% NOSE score 
reduction . 
Seconda ry Endpoints  1.Responder Rate at 7 days, 30 days, and 6 , 12, 18 , and 24
months;
2.Frequency of procedure -related adverse events (non-serious
and serious) , assessed at the index procedure and through the
7-day, 30-day, 3-month, 6-month, 12-month, 18-month, and
24-month follow -up time points ;
3.Frequency of device -related adverse events (non-serious and
serious) , assessed at the index procedure and through the 7-
day, 30 -day, 3 -month, 6 -month, 12 -month, 18-month, and 24 -
month follow -up time points;
4.NOSE score, change from baseline, to the 7 -day, 30 -day, 3-
month, 6- month, 12-month, 18-month, and 24 -month follow -
up time points;
5.Assessment of Nasal Breathing using a Visual Analogue
Scale , change from baseline, to the 7 -day, 30 -day, 3- month,
6-month, 12- month, 18- month , and 24 -month follow -up time
points;
Spirox, Inc. 
LATERA RCT  Version 3.0 
23 March 2018  
  
 
LATERA RCT  Page 11 CONFIDENTIAL  6. Endoscopic lateral wall insufficiency (LWI) score as assessed 
by independent reviewers , change from baseline  to the  3-
month and 6 -month time point ; 
7. Epworth Sleepiness Scale (ESS) score and Pittsburgh Sleep 
Quality Index  (PSQI) , change from baseline, to the 7 -day, 30 -
day, 3 -month, 6 -month, 12-month, 18-month, and 24- month 
follow -up time points . 
All secondary endpoints will be assessed for the Sham Control Arm 
at two additional visits.  The Sham arm will have  follow up vis its at  
7 days, 30 days, and 3 months  after randomization, and at 30 days, 
3-months, 6, months, 12 months, 18 months, and 24 months after 
cross  over. 
Inclusion Criteria  Subjects must meet the following criteria to be included in the study:  
1. Adults  aged 18 and above;  
2. Understand s and provide s written  informed consent;  
3. Stated willingness to comply with all study procedures, post -
treatment care and availability for the duration of  the study 
follow up of 2 years;  
4. In good general health as ev idenced by m edical history;  
5. NOSE  score  ≥55;  
6. Dynamic bi -lateral nasal wall insufficiency as confirmed by 
Positive Modified Cottle Maneuver;  
7. Nasal and facial anatomy appropriate to receive the Latera 
Implant ; 
8. Documented f ailure of benefit after at least 4 weeks of 
conservative medical management, including, for example, 
antihistamines or nasal steroids, evidenced by lack of efficacy  
or tolerability.  
Exclusion Criteria:  Subjects meeting any one of the following criteria will be excluded 
for the study:  
1. Unable to tolerate or not a candidate for procedures performed 
under local anesthesia;  
2. Pathology other than lateral wall insufficiency (e.g. septal 
deviation, turbinate or adenoid hypertrophy, polyps, sinusitis, 
rhinitis) is the primary contributor to airw ay obstruction;  
3. Requires or is anticipated to require any other concurrent nasal 
procedures (e.g. Functional Endoscopic Sinus Surgery 
(FESS), rhinoplasty, sinuplasty, septoplasty, or turbinate 
Spirox, Inc. 
LATERA RCT  Version 3.0 
23 March 2018  
LATERA RCT  Page 12 CONFIDENTIAL  reduction) outside of the index procedure within 12 months 
after the index procedure;  
4.FESS, sinuplasty, septoplasty, inferior turbinate reduction , or
rhinoplasty within the past 6 months;
5.Any other rhinoplasty procedures are planned  or planned
usage of external dilators within 24 months after the index
procedure;
6. Permanent nasal implant of any type (e.g. autologous,
homologous, or synthetic graft ) or dilator;
7.Presence of c oncomitant inflammatory or infectious conditions
or unhealed wounds in the treatment area (e.g., vestibulitis,
vasculitis, active acne),
8. C urrently us ing chronic systemic steroids or recr eational intra -
nasal drugs;
9. C urrently has  cancerous or pre -cancerous nasal lesion s, has
had radiation in the treatment area, or is currently receiving
chemotherapy;
10. History of a significant healing disorders  including
hypertrophic scarring, or keloid formation;
11. Poorly controlled diabetes mellitus;
12. Known or suspected allergy to PLA or other absorbable
implant materials in the Latera Implant ;
13. Severe obstructive sleep a pnea ( OSA ) and cannot or is
unwilling to refrain fro m continuous positive airway pressure
(CPAP ) for up to 2 weeks post -procedure  based on expected
healing needs  and mask types , in agreement with the treating
physician;
14. Female subjects, of child bearing potential, known or
suspected to be pregnant or are lactating;
15. Any other presenting condition that, in the medical opinion of
the investigator,  would disqualify the subject from the study.
Independent Medical Monitor  An independent Medical Monitor (MM) will review all adverse 
events  (AE) .  The MM will MedDRA  code each  AE and classify the 
events  with respect to device and procedure relatedness, seriousness, 
and severity.  When an AE is device- related  (ADE) , the MM will 
determine whether the A DE is anticipated or unanticipated and will 
confer with Sponsor for c onfirmation when deemed to be 
unanticipated .  
Spirox, Inc. 
LATERA RCT  Version 3.0 
23 March 2018  
LATERA RCT  Page 13 CONFIDENTIAL  Data Monitoring Committee  An independent DMC  will review safety data , study execution and 
interim analyses per the statistical plan at predetermined time points 
and as requested by  the S ponsor, the MM, or the DMC  Chair. The 
DMC  will make recommendations on protocol modifications and 
continuation of the study. 
Principal Investigator s Pablo Stolovitzky, MD  
ENT of Georgia  
5673 Peachtree Dunwoody Rd, Suite 150 
Atlanta, GA 30342 
404-297- 4230 
stol@entofga.com  
Doug Sidle , MD 
Northwestern University  
Feinberg School of Medicine  
NMH/Galter Room 15 -200 
675 N. Saint Clair  
Chicago, IL  60611 312-695- 8182 
dsidle@nmff.org  
Spirox, Inc. 
LATERA RCT  Version 3.0 
23 March 2018  
  
 
LATERA RCT  Page 14 CONFIDENTIAL  1. INTRODUCTION 
1.1. Background on Nasal Valve Collapse 
Nasal airway obstruction can be caused by several independent or concomitant factors including septal 
deviation, enlarged turbinates or a weakened nasal lateral wall, leading to nasal valve collapse (NVC). The nasal valve, first described in the early 20th century by M ink,
1 is a complex, three -dimensional, 
dynamically -alternating structure that controls nasal airflow r esistance.  A dysfunction of the nasal valve 
can lead to nasal obstruction with a significant drop in t he quality of life for patients .2   
Even a small decrease in the cross -sectional area of the nasal valve can contribute to airway obstruction.  
This is due to the Hagen –Poiseuille law which describes flow through a tube as proportional to the 4th 
power of the radius of the tube and inversely proportional to the pressure difference across the tube.   
Common causes of NVC are prior rhinoplasty, aging, nasal trauma and congenital abnormalities that 
weaken the nasal cartilage, leading to a lateral wall weakness or insufficiency (LWI) .3,4 
Therapies to correct NVC range have been limited.  These include invasive surgical procedures and non -
surgical solutions to temporarily dilate the nasal valve, such as Breathe Ri te® strips or nasal cones.  
Surgical strategies that involve septoplasty5 or inferior turbinate reduction6 may alleviate impaired nasal 
breathing, but do not directly address the weakened lateral wall. Procedures intended to stabilize the lateral wall include cartilaginous g rafts typically harvested from the nasal septum,
7 ear,8 or rib cartilage.9  
These grafts can be placed as lateral crural strut grafts,10 alar batten grafts11 or butterfly grafts.12  Implants 
made from non- absorbable alloplastic materials have also been used for treatment of NVC including 
expanded polytetrafluoroethylene13 and high -density porous polyethylene.14 These materials have not 
gained wide utilization as they require invasive surgical procedures and are as sociated with increased 
risks of infection, extrusion, and the potential need for revision procedures.  
Surgery to strengthen the lateral wall has been shown to significantly improve the quality of life for 
subjects suffering from nasal airway obstruction,15 however current procedures are generally invasive 
and have the potential to permanently alter the patient’s appearance.16  This study utilizes a minimally 
invasive technique to address NVC by supporting the nasal later al wall cartilage with an absorbable 
implant.  
Spirox has developed the Latera Absorbable Nasal Implant and Delivery Device, to enable a less invasive alternative to current surgical approaches used to suppor t weak lateral wall cartilage. This device has 
been cleared by the US Food and Drug Administration (FDA) and is currently in commercial distribution.   
1.2. Prior Investigations  
There have been three prior investigations of the Latera device, including an initial  study performed in 
Germany, the LATERAL OR  study, and the LATERAL Office study . 
Spirox, Inc. 
LATERA RCT  Version 3.0 
23 March 2018  
  
 
LATERA RCT  Page 15 CONFIDENTIAL  Initial German Study  
The initial study sponsored by Spirox was a prospective, multicenter, non -randomized, single -arm trial 
(NCT# 02188589), implanting the device in 30 subjects at three inve stigational sites in Germany.a 
Subjects with nasal valve collapse due to weakened lateral cartilage were included, and the device was 
used to support the upper and lower lateral nasal cartilage.  Fifty -six devices were implanted in 30 
subjects, who were then followed for 24 months.    
Safety data was assessed at three (3) months as the primary safety endpoint, with 5 implant/device related events in 4 subjects. These events included 3 extrusions (device required retrieval), 1 hematoma, and 1 
subject with inflammation, accounting for a per subject device -related adverse event (AE) rate of 13%. 
The device extrusions were internal nasal cavity extrusions related to the implantation technique or nasal 
manipulation by the subject. None of these events were associated with signs of tissue rejection for foreign body response and all occurred within the first postoperative month. The implanted devices were 
uneventfully removed with forceps at the time of the observation and no open surgical intervention was 
required. Each event resolved without f urther clinical sequelae.  
Effectiveness of the device was assessed using the  NOSE scores through follow -up time points  at 1 
month, 3 months, 6 months, 12 months, 18 months, and 24 months .  The NOSE score is a validated 
scori ng system for nasal obstruction.
17 The NOSE scores are assessed using a validated questionnaire 
using patient responses to a set of five (5) questions.  A percent responder rate was calculated at each follow up time  point to asses s the proportion of subjects that noted a benefit.  Responder Rate is defined 
as the proportion of subjects with at least one (1) NOSE class improvement or at least 20% NOSE score reduction.  The NOSE Categories are as follows: mild 5 -25 points, moderate 55- 75 points, extreme 80 -
100 points .  The responder rate was 86.7% at 1 month, 86.2% at 3 months, and continued improvement 
of 80% at 24 months. External and internal physical examination findings were normal, without evidence 
of implant migration. Results from an independent physician review of collected photographs 
demonstrated an adverse cosmetic effect at the 3 -month follow -up time point in 1/30 subjects (3%).  
Figure 1 (page 16, below ) summarizes the study results.  The 12-month results were reported in the 
medical literature  in April 2017.  The 24 -month follow up was completed in July 2017. 
In summary, the results of the first 30 -subject clinical trial demonstrated safety and effectiveness of the 
device for the support of upper and lower lateral cartilage. The per subject A DE rate was comparable to 
the rates reported in published studies of other alloplastic materials used to provide lateral cartilage 
support in similar study populations.  
 
                                                      
a The INEX device was used in this study, a predecessor device of Latera. Latera is substantially equivalent to INEX, 
with modifications to device packaging and changes to enhance usability.  
Spirox, Inc. 
LATERA RCT  Version 3.0 
23 March 2018  
  
 
LATERA RCT  Page 16 CONFIDENTIAL   
 
Figure 1. 24-Month Results from Spirox First Study ; Percent Responders (NOSE Score ) 
 
Additional Studies  
Spirox is currently sponsoring two additional studies on the Latera Implant, LATERAL OR and 
LATERAL Office studies (NCT#02952313 and NCT#02964312, respectively). While enrollment was 
very recently completed, some unmonitored, unpublished study results are available.  Please note:  these 
data are provided to share Latera experience in a broader patient population and based in the U.S.  Current 
data is preliminary and is subject to change.  
The LATERAL OR and Office clinical trials are designed for data collection and reporting on the Latera Nasal Implant.  Three hundred and thirty (330) subjects  with nasal valve collapse due to weakened lateral 
cartilage were enrolled, and the device was used to support the upper and lower lateral nasal cartilage.  These studies do allow for concomitant procedures such as septoplasty and turbinate reduction, as additional interventions for NAO beyond the Latera NVC intervention. Table 1 ( below ) summarizes 
information available to date (n=278 ) and the completed study above.  A comprehensive review of all 
available clinical data on the Latera Absorbable Nasal Implant shows consistent results in improvements 
in nasal breathing.  Adverse device effects are few and are non -serious. 

Spirox, Inc. 
LATERA RCT  Version 3.0 
23 March 2018  
LATERA RCT  Page 17 CONFIDENTIAL  Table 1. Outcome in the three  Latera studies 
LATERAL OR  LATERAL Office  Initial German Study  
Subjects Treated  113 165 30 
1-M Responder Rate  96/104 (92.3%)  135/152 (88.8%)  26/30 (86.7%)  
3-M Responder Rate  79/83 (95.2%)  80/91 (87.9%)  25/29 (86.2%)  
6-M Responder Rate  37/39 (94.9%)  28/35 (80.0%)  24/30 (80.0%)  
24-Month Responder Rate  Follow up in progress  Follow up in progress  20/25 (80.0%)  
Retrieval Rate* 5/223 (2.2%)  14/317 (4.4%) 3/56 (5.4%)  
All ADE (all events)  6 15 5 
ADE Rate†  5 / 223 (2.2%)  14 / 317 (4.4%)*** 4/30 (1 3%) 
Serious ADE Rate†  0 (0%)  0 (0%)  0 (0%)  
*Retrievals/Implants
†Events per Subjects Treated
1.3. Current Study: The Latera Randomized Controlled Trial 
Spirox is sponsoring a clinical study to evaluate the performance of the device in comparison to no 
intervention, in this case, a “sham treatment”.  The study design and methods have been developed usin g 
input from previous and ongoing studies with the Latera Implant .   
This randomized, single -blind, sham -controlled, multicenter study of the Latera Nasal Absorbable 
Implant will enroll subjects with nasal valve collapse due to or primarily due to insuffic ient cartilaginous 
support of the lateral nasal wall into one of two treatment arms, a) implantation with the Latera device or 
b) Sham Control.
2. STUDY DEVICE
This is a Non -Significant Risk (“NSR”), post -marketing study and will be conducted in accordance wi th 
the requirements prescribed in 21 CFR §812.2(b). Because it is a post -market evaluation of a 510(k) 
cleared medical device in commercial distribution, used according to FDA cleared indications for use, investigational device labeling described under §812.2(b) is not required. The choice of conducting this study under §812.2(b) represents a conservative approach as the study could otherwise have been categorized as Exempted per §812.2(c).  
Spirox, Inc. 
LATERA RCT  Version 3.0 
23 March 2018  
  
 
LATERA RCT  Page 18 CONFIDENTIAL  This evaluation of the Spirox Latera  Absorbable Nasal Implant and Delivery Device is considered a NSR 
device study for the following reasons:  
• While the device is an Implant, it does not present a potential for serious risk to the health, safety, 
or welfare of a subject;  
• The device is not purported or represented to be used for supporting or sustaining human life;  
• The device is not intended for a use of substantial importance in diagnosing, curing, mitigating, or treating disease or otherwise preventing impairment of human health; and,  
• The device does not otherwise pre sent a potential for serious risk to the health, safety or welfare 
of the subject.  
2.1. Indication for Use  
The Latera Absorbable Nasal Implant is indicated for supporting nasal upper and lower lateral cartilage.  
It is cleared for commercial use in the US.  
2.2. Man ufacturer and Study Sponsor  
Spirox, Inc. 595 Penobscot Drive Redwood City, CA  94063 USA 
Study Contact:   Elisa Hebb, VP  
Clinical and Regulatory Affair s 
     ehebb@spiroxmed.com  
     650-249-6379 (O)  
2.3. Clearance Status  
Spirox received clearance from the US FDA  to market the Latera Implant  on June 23, 2016 (K161191). 
The device is Regulatory Class II, product code NHB. A predecessor of the device, the Spirox INEX 
Absorbable Nasal Implant System, was previously clea red on December 4, 2015 (K152958). The Latera 
device is similar to the original INEX Implant , with the exceptions of modifications to device packaging 
and changes to enhance usability.   
2.4. Model Numbers  
The Latera  Implant  is available in one si ze and m odel. 
2.5. Device Description  
The absorbable nasal Implant is comprised of a 70:30 blend of poly(L -lactide) and poly(D -lactide). The 
Implant is predominantly cylindrical in shape with a diameter of 1 mm and an overall length of 24 mm with a forked distal end for anchoring and features on the proximal end for increased flexibility. The copolymer is absorbed by the body over a period of approximately 18 months .
18 The Latera I mplant is 
provided in a plastic tray w ith a sliding lid.  The Implant and plastic tray are depicted in Figure 2, below . 
Spirox, Inc. 
LATERA RCT  Version 3.0 
23 March 2018  
  
 
LATERA RCT  Page 19 CONFIDENTIAL   
 
Figure 2: LATERA  Absorbable Nasal Implant and Packaging  
 
The Delivery Device is a single use device composed of an inner shaft, an outer handle with a push rod, a 
deploy button, an open button and a 16-gauge  delivery cannula with a protective cover. The inner shaft 
includes an implant loading port which enables the loading of the Implant . The inner shaft transitions 
between the loading position and the cannula to collapse the implant forks within the cannula inner lumen and prepare the Implant for deployment. The outer handle includes deploy and open buttons that  lock and 
release the handle from these respective positions. The outer handle also includes a push rod that shuttles 
the implant from the implant loading port to a ready position for deployment. The Implant Positioning 
Guide is packaged with the Delivery Device and is provided as an aid to the physician for planning the 
procedure and identifying the target Implant location. The Delivery Device and the Implant Positioning 
Guide are shown in Figure 3 below.  
 
 
Figure 3. Delivery  device and implant positioning guide. 
Implant Positioning Guide  
Distal and Proximal 
Marking Holes  
Fork Orientation 
Features  
Deploy Button  
 Open Button  
Delivery Cannula  
(Cover removed)  
Outer Handle  
Inner shaft  
Spirox, Inc. 
LATERA RCT  Version 3.0 
23 March 2018  
  
 
LATERA RCT  Page 20 CONFIDENTIAL  3. STUDY OBJECTIVES  AND ENDPOINTS 
3.1. Study Objectives  
The primary objective of the LATERA RCT is to demonstrate the superiority  of the Latera Implant  to 
improve nasal breathing , compar ed with a Sham Control  procedure.   
3.2. Primary Endpoint  
The primary endpoint of the study is the Responder Rate, assessed 3 months post -procedure in the per 
protocol population of the Latera and Sham arms . Responder Rate is  defined as the proportion of 
subjects with at least one (1) NOSE class improvement or at  least 20% NOSE score reduction. 
3.3. Secondary  Endpoints  
The following endpoints comprise the secondary endpoints and the time points that each will be assessed:  
• Responder Rate at 7 days, 30 days, and 6, 12, 18 and 24 months;  
• Frequency of procedure -related adv erse events (non -serious and serious), assessed at the index 
procedure and through the 7 -day, 30 -day, 3- month, 6 -month, 12- month, 18-month, and 24-
month follow -up time points;  
• Frequency of device -related adverse events (non -serious and serious), assessed at the index 
procedure and through th e 7-day, 30 -day, 3-m onth, 6 -month, 12- month, 18 -month and 24- month 
follow -up time points;  
• NOSE score, change from baseline, to the 7 -day, 30 -day, 3 -month, 6- month, 12 -month, 18-
month, and 24- month follow -up time points;   
• Visual Analogue Scale (VAS ), change from basel ine, to the 7 -day, 30 -day, 3 -month, 6- month, 
12-month, 18-month, and 24 -month follow -up time points;  
• Endoscopic lateral wall insufficiency (LWI) score as assessed by independent reviewers, change 
from baselin e to the 3 -month and 6- month time point s; 
• Epworth Sleepiness Scale (ESS) score  and Pittsburg Sleepiness Quality Index, change from 
baseline, to the 7 -day, 30- day, 3 -month, 6- month, 12- month, 18-month, and 24- month follow -
up time points. 
All secondary endpoints will be assessed for the Sham Control Arm at two additional visits. The Sham 
arm will have follow- up visits at 7 days, 30 days, and 3 months after the initial treatment/randomization, 
and 30 days, 3 months, 6, months, 12 months, 18 months, and 24 mont hs in subjects that cross  over. 
4. STUDY POPULATION  
Subjects will be recruited from site s’ existing patient population s that are seeking treatment for nasal airway 
obstruction including nasal valve collapse.  Anatomical considerations may impact the race dist ribution 
(e.g. some races may be less prone to lateral wall collapse) , but the intention is  to enroll all eligible subjects.   
Spirox, Inc. 
LATERA RCT  Version 3.0 
23 March 2018  
LATERA RCT  Page 21 CONFIDENTIAL  Study brochures containing information on study participation and the Latera Implant may be provided to 
the sites, as well as posters that may be displayed either as hard copies or electronically on computer monitors in the office.  All recruiting materials must be approved by the appropriate IRB (central or local).  
4.1. Patient Eligibility  
The trial will include up to 150 subjects at up  to 15 investigational sites, male and female , aged 18 and 
above who are appropriate candidates for nasal intervention with the Latera Implant . 
Inclusion Criteria  
Subjects must meet the following criteria to be included in the study: 
1.Adults aged 18 and above;
2.Understands and provides written informed consent;
3.Stated willingness to comply with all study procedures, post -treatment care and availability for
the duration of the study follow up of 2 years;
4.In good general health as evidenced by medical history;
5.NOSE score ≥55;
6.Dynamic bi -lateral nasal wall insufficiency as confirmed by Positive Modified Cottle Maneuver;
7.Nasal and facial anatomy appropriate to receive the Latera Implant;
8.Documented failure of benefit after at least 4 weeks of conservativ e medical management,
including, for example, antihistamines or nasal steroids, evidenced by la ck of efficacy or
tolerability.
Exclusion Criteria  
Subjects meeting any one of the following criteria  are ineligible for study participation: 
1.Unable to tolerate  or not a candidate for procedures performed under local anesthesia;
2.Pathology other than lateral wall insufficiency (e.g. septal deviation, turbinate or adenoid
hypertrophy, polyps, sinusitis, rhinitis) is the primary contributor to airway obstruction;
3.Requires or is anticipated to require any other concurrent nasal procedures (e.g. Functional
Endoscopic Sinus Surgery (FESS), rhinoplasty, sinuplasty, septoplasty, or turbinate reduction)
outside of the index procedure within 12 months after the index proced ure;
4.FESS, sinuplasty, septoplasty, inferior turbinate reduction, or rhinoplasty within the past 6
months;
5.Any other rhinoplasty procedures are planned or planned usage of external dilators within 24
months after the index procedure;
6.Permanent nasal implant of any type (e.g. autologous, homologous, or synthetic graft) or dilator;
7.Presence of concomitant inflammatory or infectious conditions or unhealed wounds in the
treatment area (e.g., vestibulitis, vasculitis, active acne),
Spirox, Inc. 
LATERA RCT  Version 3.0 
23 March 2018  
  
 
LATERA RCT  Page 22 CONFIDENTIAL  8. Currently use of chronic syste mic steroids or recreational intra -nasal drugs;  
9. Currently has cancerous or pre -cancerous nasal lesions, has had radiation in the treatment area, or 
is currently receiving chemotherapy;  
10. History of a significant healing disorders including hypertrophic scarr ing, or keloid formation;  
11. Poorly controlled diabetes mellitus;  
12. Known or suspected allergy to PLA or other absorbable implant materials in the Latera Implant; 
13. Severe obstructive sleep apnea (OSA) and cannot or is unwilling to refrain from continuous 
positiv e airway pressure (CPAP) for up to 2 weeks post -procedure  based on expected healing 
needs and mask type, in agreement with the treating physician;  
14. Female subjects, of child bearing potential, known or suspected to be pregnant or are lactating;  
15. Any other presenting condition that, in the medical opinion of the investigator, would disqualify 
the subject from the study. 
4.2. Patient Screening and Informed Consent  
The investigator or designee, who is trained on the study protocol, will review and explain the study 
protocol and information, including the potential risks and benefits of participation.  Time will be made available for the patient to read through the materials  and ask questions .  A study and protocol -specific 
Informed Consent Form (ICF), approved by a ce ntral or appropriate local  Institutional Review Board 
(IRB) will be obtained from each subject prior to enrollment in the study. An electronic consent (eConsent) will be available on a web -based module of the study’s electronic data capture (EDC) system. 
Alternatively, Investigators may utilize a standard written consent form. In either case, subjects will be 
provided with a hardcopy of the executed ICF. All subjects will be instructed that they are free to decline 
entry into the study or to withdraw from t he study at any time without prejudice to future treatment. After 
completion of the consenting process  and eligibility has been confirmed, subjects will be considered 
consented and enrolled for the study duration of up to 27 months of follow -up.  
4.3. Subject  Disposition and Flow Chart  
The graphic below  illustrates the flow of subjects in the study and potential points of study exit relative 
to analysis plan  (Figure 4, page 23, below ). Subjects are enrolled at the time of consent, and the ITT 
population is comprised of all consented subjects. Subjects are randomized after the anesthetic is 
administered. Subjects in the active treatment group receive the Latera implant , while those in the Sham 
Control group will undergo insertion of the cannula  into the nasal lateral wall , but the Latera will not be 
implanted. T he mITT  population includes all subjects who were randomized, irrespective of whether they 
received the study device. The PP population includes those subjects who received the study device or 
the Sham Control and who are followed through 3 months.  
Spirox, Inc. 
LATERA RCT  Version 3.0 
23 March 2018  
LATERA RCT  Page 23 CONFIDENTIAL  Figure 4. Flow of subjects in the trial  and definitions of the ITT, mITT and PP populations.  
4.4. Withdrawals and Loss to Follow- up 
Participation is completely voluntary and each subject is free to withdraw from the study at any time. An 
investigator also has the right to withdraw the subject from the study in the event of reasons concerning 
the health or well -being of the subject, or in the case of lack of cooperation. Should a subject decide to 
withdraw for any reason, or should the inve stigator decide to withdraw the subject, all efforts will be 
made to complete and report the observations up to the time of withdrawal as thoroughly as possible. A 
complete final evaluation at the time of the subject’s withdrawal must be made and an explan ation given 
of why the subject is withdrawing or being withdrawn from the study. 
The reason for and date of withdrawal must be recorded on the subject’s Study Exit Case Report Form 
(CRF). If the reason for the withdrawal is a device -related or procedure related AE, the event must be 
reported to the Sponsor and recorded in the  AE CRF.  
Withdrawal can occur  at several time -points that would impact the follow up schedule for a study subject. 
If withdrawal occurs any time  before the treatment procedure, anesthesia and randomization, the subject 
will be exited with no  follow up assessment requirements.  If withdrawal occurs after anesthesia, 

Spirox, Inc. 
LATERA RCT  Version 3.0 
23 March 2018  
LATERA RCT  Page 24 CONFIDENTIAL  regardless of whether randomization is complete, subjects will be followed through the 3 months follow 
up assessment and then exited from the study.   
All efforts will be made to retain subjects  in order to collect data at all the follow -up visits (7 days, 30 
days, 3 months, 6 months, 12 months , 18 months, 24 months). Due diligence in reaching the subject must 
include:  
•Two documented telephone contact attempts, emails, or regular postal mail letters, and
•A certified letter
After the above attempts are made, if no response is obtained, the Study Exit CRF page will need to be 
completed and communication attempts will need to be documented.  
5.STUDY PROCEDURES AND FOLLOW-UP EVALUATIONS
5.1. Screening/Baseline Assessment
All patients  seeking treatment for nasal obstruction will be screened for eligibility according to the
inclusion/exclusion criteria.  A member of the  site’s  research team will review the patient’s medical
history for eligibility and potential inclusion into the study.
The Investigator  or their designee will inform the patient about the purpose of the study and will explain
the potential benefits and risks of both study arms, the Latera Implant and/or the Sham Control arm .
Potential subjects will be counseled as to t he nature of their condition. All subjects will have ample time
to ask questions.Patients  indicating that they would like to proceed with study participation, and who are willing to comply 
with the requirements of the study protocol, will be asked to sign an Informed Consent Form (ICF) t hat
has been approved by the governing IRB.  Failure to provide written informed consent makes  the patient
ineligible for the study.
Female patients  of childbearing potential will undergo a pregnancy test to verify eligibility. Women of
childbearing potential are defined as any female who has experienced menarche and who is NOT
permanently sterile or postmenopausal.  Postmenopausal is defined as twelve (12) consecutive months
with no menses without an alternative medical cause.
Patients will be considered enrolled as study subjects upon signing the ICF and meeting all study
eligibility criteria. Once the subject has been enrolled into the study a baseline assessment will be
completed .
The following baseline data will be collected at the Screening/Baseline visit prior to the procedure. All
data must be recorded in the study specific EDC for Latera RCT within 5 business days.
•Nasal Obstruction Symptom Evaluation (NOSE) scale
Spirox, Inc. 
LATERA RCT  Version 3.0 
23 March 2018  
LATERA RCT  Page 25 CONFIDENTIAL  •Epworth Sleepiness Scale (ESS)
•Pittsburg Sleep Quality Index (PSQI)
•NAO Breathing Assessment
•Demographic information
•Abbreviated Medical History
•Nasal medical history including risk factors
•Nasal Exam including assessment of the septum and turbinates
•Modified Cottle Ma neuver
•Lateral Wall Motion Video
•Latera™ Implants may involve unknown risks to a pregnant woman, an embryo, fetus (unborn
baby) or nursing infant.  Any female that is  pregnant, planning to become pregnant or is
breastfeeding a child, cannot participate in this study. All women of childbearing potential will
have a pregnancy test done prior to treatment.
Adverse events that occurred after the ICF was signed, should be entered in the EDC within 1 business 
day of completion of the visit.  
Treatment must occur within 30 days of the date of consent .  If the subject is not treated within 30 days, 
they will be exited from the study with no further follow -up. 
5.2. Treatment Visit  
The Schedule of Study Activities is located below in Table 2.  Refer to the Instructions for Use (IFU) for 
device de ployment techniques in Attachment C.   
The treatment procedure must be completed in an office setting using standard aseptic techniques.  Local anesthesia per the site’s standard of care practice will be administered to the subjects in each study arm. 
Anesthesia techniques will be documented.  Once the anesthesia has been administered the subject will be randomized into either the Sham Control Arm or the Latera Treatment Arm.   
NOTE:  Randomization will be facilitated using an electron ically secure table t computer  that can 
be used in the exam room setting to access site- specific randomized treatment assignments in the 
EDC . 
Optionally, an oral anxiolytic (e.g. Valium, Ativan or equivalent) and/or analgesic (e.g. Tylenol, or Tylenol with Hydrocodone  or equivalent ) may be offered to the subject prior to the procedure, per the 
investigator’s discretion, consistent with local practice standards. Procedural medications will be 
recorded. 
The below section includes a description of the activitie s occurring during the Latera Implant  or Sham 
Control procedure:  
1. Cephalexine or equivalent antibiotic may be administered to the subject before the procedure,
Spirox, Inc. 
LATERA RCT  Version 3.0 
23 March 2018  
LATERA RCT  Page 26 CONFIDENTIAL  2. Clean the skin of the nose and the mucosal surface with an antiseptic solution (e.g. isopropyl
alcohol, betadine  or equivalent ),
3.Examine nasal anatomy and mark the target trajectory for the Latera Implants with the aid of a
sterile pen and sterile Latera Implant positioning guide per IFU (Attachment C ).
4. Obtain photographs of planned implant target trajectory,
5.The following local anesthesia steps may be considered per site’s standard of care procedures to
ensure subject comfort during implant placement.
a.SPRAY: Anesthetic (e.g. lidocaine or equivalent)
b.TOPICAL: Few minutes after application of the spray, cotton balls or pledgets soaked inanesthetic (e.g. Tetracaine, 4% lidocaine  or equivalent ) may be placed in the nasal
vestibule, ensuring contact with turbinate and floor of nose posteriorly, and to lateralnasal wall anteriorly).
c.INFILTRATION:
i.Anesthetic, such as Lidocaine with Epinephrine or mixture of Lidocaine/
Epinephrine mixed with Marcaine with Epinephrine, or the equivalent, may beinjected locally.
ii.The anesthesia may be injected to achieve an infraorbital block.
iii. In addition, anesthesia may be injected along the proposed implantation track,starting at the alar rim and progressing to the supra-periosteal region of the
maxilla. Additional injections into alar rim may also be considered.
d.Wait approximately 10 minutes for anesthesia to be in ful l effect.
6. RANDOMIZATION:  Subjects are randomized into the Sham Control Arm or the Latera Implant
Treatment Arm, after  anesthetic is delivered. Treatment assignment will remain blinded to the
study subject.
7.In the event the subject is selected for the Latera Implant Arm, the implants (bilateral) will be
delivered in a loaded delivery tool, using standard deployment technique per Spirox IFU
(Attachment  C). Only one Implant per side may be placed.
8.In the event the subject is selected for the Sham Control Arm,  follow the exact same process for
implant delivery per Spirox IFU ( Attachment  C), including pulling the alar rim back allowing
insertion of the cannula of an unloaded (no implant) delivery tool.  No implant is deployed in the
Sham Control Arm.
The following data will be recorded on the subject’s procedure CRF:  
•Anesthesia regimen
•Photograph image with Trajectory Plan
•The Randomization Assignment
•All medication administered pre - and post -procedure.
•Implant placement or sham control logistical information
•Any adverse events or adverse device effects observed during this visit will be collected anddocumented.
Spirox, Inc. 
LATERA RCT  Version 3.0 
23 March 2018  
LATERA RCT  Page 27 CONFIDENTIAL  Data collected for the Treatment Visit should be entered into the EDC no later than five (5) business days 
after the completion of proced ure/visit.  
IMPORTANT : Prior to discharge, provide the post -procedure reminder form  and instructions for 
managing the post procedure recovery time.   In addition, a course  of antibiotics (e.g. Amoxicillin, 
Augmentin or equivalent) may be prescribed by the physician pursuant to local practice standards.   Upon 
completion of the treatment visit, the subject will be scheduled f or their next Follow -Up Visit.  
Note:
  Space intentionally left blank. 
Spirox, Inc. 
LATERA RCT  Version 3.0 
23 March 2018  
  
 
LATERA RCT  Page 28 CONFIDENTIAL   
5.3. Follow -Up Assessments  
For subjects randomized to the Latera Implant  arm, the follow- up evaluations will be at 7 days, 30 days, 
3 months, 6 months, 12 months, 18 months, and 24 months post -procedure.  Table 2. Schedule of Study Activities  
Visits (± Windows)  
Screening/Baseline  
Index Procedure -  Day 0 
Visit 3 - 7 ± 2 days 
Visit 4 - 30 ± 7 days* 
Visit 5 - 90 ± 14 days* 
Cross -Over Screening  
(for Sham Control Subjects  only) 
Cross -Over Procedure  
(for Sham Control Subjects o nly) 
Visit 6 – 6 month  ± 14 days 
Visit 7 – 12 months ± 30 days 
Visit 8 – 18 months ± 30 days 
Visit 9 – 24 months ± 30 days 
  
Informed Consent X     X       
Nasal Medical History & Exam  X            
Eligibility  X            
Lateral Wall Motion Video  X    X   X     
Turbinate Hypertrophy and Septum 
Assessment  X            
Nasal Obstruction Evaluation (NOSE) X  X X X X  X X X X  
Sleep Assessments (ESS & PSQI)  X  X X X X  X X X X  
Photograph – Planning Images  X            
Pregnancy T est X     X       
Nasal Breathing Assessment (VAS)  X  X X X X  X X X X  
Randomization  X           
Procedure Logistics   X     X      
 Relevant Medication s X  X X X   X X X X  
Adverse Events  X X X X X  X X X X X  
 Note:  *For Sham Control Subjects that cross -over after 90 day assessment for primary endpoint and meet stu  
eligibility for a Latera Implant, per the protocol, will have repeat 30 and 90 day visits, in addition to all the oth  
visits.   
 
Spirox, Inc. 
LATERA RCT  Version 3.0 
23 March 2018  
  
 
LATERA RCT  Page 29 CONFIDENTIAL  For subjects randomized to the Sham Control arm, the follow -up eva luation will be at 7 days, 30 days, 
and 3 months.  After the 3 -month follow -up evaluation, the subject will be eligible to cross over to the 
Latera Implant  arm, if they continue to meet the study inclusion and exclusion criteria. If the subject is 
eligible  to cross over to the Latera Treatment arm , an informed consent addendum  will need to be 
presented to the subject and signed .  If the Latera Implants are deployed, the follow -up schedule is 
restarted and occur at 30 days, 3 months, 6 months, 12 months, 18 months, and 24 months post -Latera 
Implant procedure.  If the study subject does not meet the eligibility criteria or declined to continue 
participation, the subjects will be exited.  See Section 6.2 for analysis implications.      
The schedule of study activities (Table 2, page 28, above ) specifies the assessments that will be completed 
at each follow up visit.  Below are the descriptions of the PRO assessments and Lateral Wall Motion 
Video assessment:  
Nasal Obstruction Symptom Evaluation (NOSE) scale  
The Nasal Obstruction Symptom Evaluation (NOSE) Scale is a Patient -Reported Outcome (PRO) 
instrument that will be administered to capture subject perception of the degree of nasal airway patency.17  
The NOSE scale is a validated instrument, developed by the American Academy of Otolaryngology—Head and Neck Surgery (AAO -HNS), and has been used in several clinical trials.  The scale is brief, easy 
to complete, and is an important tool for pre - and post -intervention evaluation of symptoms in subjects 
with nasal obstruction.  
Subjects will be asked: “Since your last follow up visit, how much of a problem were the following conditions for you?” Spec ifically, subjects will be asked to rate their perceptions on the Likert scale with 
respect to the following characteristics:  
• Nasal congestion or stuffiness 
• Nasal blockage or obstruction 
• Trouble breathing through my nose  
• Trouble sleeping  
• Unable to get enough air through my nose during exercise or exertion 
Subjects will rate their responses using a Likert scale with response options 0, 1, 2, 3 or 4, as follows:  
• Not a Problem  
• Very Mild Problem  
• Moderate problem  
• Fairly Bad Problem  
• Severe problem  
The responses are rated along the continuum, with a rating of “0 – not a problem” indicating no problem 
breathing, with a completely free flow of air through the nasal airway; “1 – very mild problem”, with 
Spirox, Inc. 
LATERA RCT  Version 3.0 
23 March 2018  
  
 
LATERA RCT  Page 30 CONFIDENTIAL  only slight obstruction in airflow; “2 – moderate problem”, with mouth breathing considered easier; “3 – 
fairly bad problem,” with considerable obstruction to airflow; and a rating of “4 – severe problem,” with 
complete blockage and obstruction of the nasal passageway, where the subject cannot breathe thr ough 
the nose and can only mouth breathe.   
Nasal Breathing Assessment  
A subject’s perception of breathing cannot be quantitatively measured, but exists on a continuum from 
the subject perspective.  The  VAS  is a PRO instrument that will be used to capture subjects’ perception 
of their ability to breathe through the nose, allowing subjects to indicate the degree of breathing difficulty 
(or ease) they are currently experiencing.  
Operationally, the  VAS is a horizontal line, 100mm in length, anchored by word descriptors at each end, 
as illustrated in Figure 3 . The subject will mark on the line the point that they feel represents their 
perception of their current state and the electronic P RO form will automatically calculate the score for 
VAS.  The VAS score is determined by measuring in millimeters from the left end of the line to the point 
marked by the subject.  
 
No difficulty/  
Easy to Breathe 
Through the Nose  
  
 Unable to 
Breath e 
Through the 
Nose  
 
 
 
Figure 3: Visual Analog Scale.  Left side represents 0  mm and right side represents 100  mm. 
Epworth Sleepiness Scale (ESS)  
The Epworth Sleepiness Scale (ESS) is a widely -used PRO in the field of sleep medicine as a subjective 
measure of a patient's sleepiness.   
The test is a list of eight situations that evaluate a subject’s tendency to become sleepy on a scale of 0 (no chance of dozing), to 3 (high chance of dozing). The scale estimates whether the subject is experiencing excessive sleepiness that may possibly require medical attention.  

Spirox, Inc. 
LATERA RCT  Version 3.0 
23 March 2018  
  
 
LATERA RCT  Page 31 CONFIDENTIAL  Subjects will be asked: “How sleepy are you?  How likely are you to doze off or fall asleep in the 
following situations? ”  They will be asked to rate their chances of dozing off, not just feeling tired and 
even if they have not done some of these things recently to try and determine how they would have 
affected them .  For each situation, subjects will be asked to decide if they would have:  
• No chance of dozing    0 
• Slight chance of dozing   1 
• Moderate change of dozing   2 
• High chance of dozing   3 
Using the above scale, subjects  will write down the corresponding choi ce to the following situations: 
• Sitting and reading  
• Watching TV  
• Sitting inactive in a public place (e.g. a theater or a meeting) 
• As a passenger in a car for an hour without a break  
• Lying down to rest in the afternoon when circumstances permit  
• Sitting and talking to someone  
• Sitting quietly after lunch without alcohol  
• In a car, while stopped for a few minutes in traffic  
The responses to the above situations is totaled for a final composite score.    
Pittsburg Sleep Quali ty Index 
The Pittsburgh Sleep Quality Index ( PSQI ) is a questionnaire  used to assess sleep quality over the 
previous 1 -month.  The measure consists of 19 individual items (see CRF), creating 7 components that 
produce one total score. Component scores consist of subjective sleep quality, sleep latency (i.e., how long it takes to fall asleep), sleep duration, habitual sleep efficiency (i.e., the percentage of time in bed that one is asleep), sleep disturbances, use of sleeping medication, and daytime dysfunction. 
Lateral Wall Motion Video Assessment  
Video results from Endoscopy assessments will be captured and transferred to Spirox.  The videos will 
be de -identified prior to transfer to an independent reviewer.  The independent reviewer will make 
assessment of endoscopic lateral wall insufficiency score (1, 2 or 3).19 
5.4. Retrievals and Re -Implantation 
There is a low in cidence of where the Latera Implant is removed, post -implant nasal manipulation by a 
patient.  If this occurs, the Latera Implant may be re-implanted, within 30 days , of the removal  at the 
discretion of the investigator, continuing the follow up schedule from  the Index Procedure .   An 
addendum to the Informed Consent is required to be  reviewed and signed by subject .  See Section 6.2 
for analysis implications.      
Spirox, Inc. 
LATERA RCT  Version 3.0 
23 March 2018  
  
 
LATERA RCT  Page 32 CONFIDENTIAL  6. STATISTICS AND DATA ANALYSIS 
This is a prospective, randomized, sham- controlled, single -blind, multi- center , post- market trial of the 
Latera Implant vs. Sham Control  in subjects with nasal valve collapse due to or primarily due to insufficient 
cartilaginous support of the lateral nasal wall . The trial will enroll up to 150  subjects at up to 15 
investigational sites in the US. 
6.1. Hypothesis  
The primary endpoint of the study is defined as the proportion of responders at 3 months following the 
index procedure .  Responder is defined as a subject that has at least one (1) NOSE class improvement or 
at least 20% NOSE score reduction from baseline to 3 months post treatment.  
The treatment (p T) and control (p C) will be compared using a 1-sided test for  superiority of  the following 
hypothesis:  
H0:   pT ≤ p C versus  H A:  p T > p C 
6.2. Study Populations  
Adult male and female patients presenting with symptomatic nasal valve collapse due to or primarily due to insufficient cartilaginous support of the lateral nasal wall will be enrolled, if they meet all eligibility 
criteria.  The study will inc lude up to 150 subjects enrolled at up to 15 investigational sites in the US.  
The maximum enrollment per site will be 20% of the total enrollment number therefore a 30 -subject 
maximum per site.   Initial site enrollment will be limited to 20 -subjects and w ritten permission from 
Sponsor will be required to enroll up to 30 subjects ma ximum.  
The following populations will be analyzed in the study:  
Intention- to-Treat (ITT) Population:  The ITT analysis will be performed on all enrolled subjects 
in the study , irrespective of adherence with the entry criteria, treatment actually received, subsequent 
withdrawal, or deviation from the Clinical Investigational P lan.20 Subjects who are enrolled but not 
randomized will not be included in the analytic datasets.  
Modified Intention- to-Treat (mITT) Population: The mITT Population will comprise of ITT 
subjects who received anesthetic, regardless of whether they  received the Latera Implant  or 
underwent the Sham procedure. Subjects who are in the mITT population assigned to the  Latera 
Implant  Arm but who do not receive the device are followed for 3 months  for safety -related 
endpoints  and will be exited after 3-month follow -up assessments.   
Per Protocol Population:  The PP analysis will be performed on randomized subjects a) in t he Sham 
Control Arm, and b) in the Latera Implant  Arm who were treated and who had NOSE score 
assessments within the 3 -month follow -up clinic visit window. The primary endpoint will be 
Spirox, Inc. 
LATERA RCT  Version 3.0 
23 March 2018  
  
 
LATERA RCT  Page 33 CONFIDENTIAL  evaluated on this population.   Subjects will be analyzed according to t he procedure actually received 
in the event of mis -randomization.  
The point of enrollment into the study occurs when the subject signs the ICF  and meets all eligibility 
criteria .  
6.3. Unblinding and Crossover Subjects  
All s ubjects will be un -blinded after the assessment is complete  at the 3 -month time point .  If the subject 
is in the Sham Control group, a Latera implant  may be implanted if they meet the eligibility criteria . 
Subjects who are un -blinded (within either treatment arm) prior to the 3 -month time  point will be 
excluded from the per protocol  analysis  dataset for primary and secondary analysis endpoints. However,  
data will continue to be recorded through the 24 -month follow -up time  point  for these subjects . 
Sham Control subjects may not recei ve a nasal implant prior to the 3 -month primary endpoint assessment.  
Cross -over subjects will have 2 additional visits as they will begin follow -up time  points again once they 
have received the Latera Implant . 
6.4. Sample Size  
The primary analysis will be based on a 1 -sided binomial test of proportions. Assuming a Sham Control 
response rate of 40% and a Latera Treatment response rate of 70% at month 3, a maximum sample size 
of 124 evaluable subjects is required for 90% power and preserving a 2.5% (one -sided) ty pe I error rate. 
This study is designed as a group -sequential trial with 2 interim analyses and a final analysis. The stopping 
boundaries are derived using the Triangular Method [1], which is a special case of Unified Family 
(Power) boundaries. A shape parameter of 0.65 will be used, and both boundaries will be non -binding.  
Interim analyses will occur when approximately 20 and 60 total subjects have been enrolled. The Latera 
response rate has been observed at approximately 85% in single -arm trials, and is likely to be slightly 
lower in a single blind setting. Thus, 70% is likely a conservative estimate. The placebo response rate 
observed in pain trials is approximately 30%, and may be even higher in a procedural setting, so 40% 
was selected for the  control response rate used in the study design calculations.  
Assuming up to a 10% drop out rate and a 10% potential retrieval rate, the sample size is adjusted up to 
150 subjects will be enrolled  to assure adequate sample size with 3 months follow up will be enrolled. 
6.5.    Missing Data  
Every effort will be made to minimize the amount of missing data.  Recognizing the difficulty of avoiding 
some missing data, however, data imputation methods with sensitivity imputation analyses will be pre -
specified in t he Statistical Analysis Plan. The robustness of the multiple imputation  based sensitivity 
analyses for the primary outcome will be tested with a tipping point analysis encompassing all possible 
imputation outcomes.   
Spirox, Inc. 
LATERA RCT  Version 3.0 
23 March 2018  
  
 
LATERA RCT  Page 34 CONFIDENTIAL  6.6. Demographics and Baseline Characteristi cs 
The baseline demographics and anatomic characteristics of the treatment groups will be presented with 
descriptive statistics.  
6.7. Changes to Planned Analyses 
All analyses will be detailed in the Statistical Analysis Plan (SAP). Any changes to the planned analyses 
will be documented as amendments to the SAP and in the study report. 
6.8. Interim Analyses  
There will be two planned interim analyses for this study ( Table 3, below ). The stopping boundaries are 
moderately aggressive for both effectiveness  and futility to reduce the number of subjects enrolled  if clear 
evidence of effectiveness  or futility becomes apparent during the trial. When the design assumptions are 
correct (40% versus 70%), the chance that the trial will stop for effectiveness at the second interim 
analysis is about 1 in 3. However, if t he Latera rate is 85% as seen in the single arm studies, the chance 
of stopping for effectiveness  at the second interim analysis is better than 8 in 10. While all evaluable 
subjects enrolled at the time of the interim analysis would be followed through 3 months and included in 
the primary endpoint, an early termination at the second interim analysis could save 20 -30% of the total 
sample size, depending on the enrollment rate. 
Interim analyses will be carried out by an independent statistician and reviewed b y the independent DMC . 
Details of the interim analysis plan and additional operational details will be found in the Statistical 
Analysis Plan and the DMC  Charter . 
Table 3. Planned analyses 
    Boundaries  
(p-value)  Cumulative Error 
Spending  
 Analysis  Evaluable  
(n) Futility  Efficacy  Type II  Type I  
Interim 1  22 0.7921  0.0005  0.0106  0.0005  
Interim 2  60 0.2139 0.0090 0.0548 0.0093 
Final  124 0.0194 0.0194 0.1000 0.0250 
 
7. STUDY MANAGEMENT CONSIDERATIONS 
7.1. Data Management: Collection of Clinical Data  
The Sponsor and/or assigned designee will be responsible for the processing and quality control of the 
data. All other source data, source documents, CRFs, copies of protocols and protocol amendments, 
device accountability forms, correspondence, subject identification lists, informed consent forms, and other essential documents must also be retained for a period of at least 2 years.    
Spirox, Inc. 
LATERA RCT  Version 3.0 
23 March 2018  
  
 
LATERA RCT  Page 35 CONFIDENTIAL  No study document or image will be destroyed without prior written agreement between the Sponsor and 
the Inve stigator. Should the Investigator wish to assign the study records to another party or move them 
to another location, advance written notice must be given to the Sponsor.  
7.2. Protocol Amendments  
Protocol amendments are the sole responsibility of the Sponsor.  No changes from the final approved 
(signed) protocol will be initiated without the IRB’s prior written approval or favorable opinion of a written amendment, except when necessary to eliminate immediate hazards to the subjects or when the 
change involves only logistics or administration. The Principal Investigator will acknowledge the 
amendment by signing the Protocol Agreement. 
7.3. Protocol Deviations  
A protocol deviation is the non -adherence to o r divergence from the protocol -specific study procedures. 
The following are all considered protocol deviations: inclusion of subjects outside the eligibility , visits 
outside the scheduled visit windows, missed data collection at visits, improper or lack of consent, lack of 
IRB approval , lack of a dherence to ra ndomization and procedural methods.  A protocol deviation 
undertaken to protect the life or physical well -being of the patient in an emergency is a special 
circumstance that must be reported to the Sponsor and the reviewing IRB within 5 working days. No 
other type of prospective protocol deviation is permitted without prior written approval  from the study 
Sponsor. A record of all protocol deviations will be maintained and reviewed throughout the conduct of the study. The Sponsor will address deviations and take  appropriate corresponding and corrective action. 
Continued non -compliance with the study protocol may lead to termination of the Investigator’s 
participation in the study. 
7.4. Information to Study Personnel  
The Investigator is responsible for giving information about the study to all staff members involved in 
the study or in any element of subject management, both before starting the study procedures and during 
the study (e. g., when new staff become involved). The Investigator must ensure that all study staff 
members are qualified by education, experience, and training to perform their specific responsibilities. 
The Sponsor or its designee  is responsible for explaining the CIP to all study staff, including the 
Investigator, and for ensuring their compliance with the protocol throughout the study. Additional 
information will be made available during the study when new staff become involved in the study, and 
as otherwise agreed upon with either the Investigator or the monitor. 
8. RISK-BENEFIT ANALYSIS 
8.1. Risks to the Su bjects 
The l ist below described the general types of potential risks to the study subjects.  
Spirox, Inc. 
LATERA RCT  Version 3.0 
23 March 2018  
  
 
LATERA RCT  Page 36 CONFIDENTIAL  Adverse Events 
Infection  
Inflammation  
Pain or discomfort  
Serous wound drainage  
Hematoma  
Ecchymosis 
Extrusion  
Retrieval  
Foreign body reaction 
Foreign body sensation  
Device Fracture 
Device Malposition or Migration  
Device Palpable  
Skin Irritation  
Allergic reaction to device  
Allergic reaction to medications from procedure or follow up  
Allergic reaction to any study related medications  
Hematoma *, genera l (such as cannula insertion, delivery of anesthetics, manipulation of nose during 
procedure, etc .) 
Perceptible cosmetic changes 
Respiratory / sinus infection or rhinorrhea  
Continued or worsened breathing symptoms  
Scarring  
Firmness, swelling, redness 
Decreased sense of smell  
*Includes hematoma from cannula insertion, delivery of anesthetics, manipulation of nose during procedure)  
 
There are other health risks and discomforts associated with the testing that the subjects will undergo 
before and after  their procedure, including but not limited to  pain and bruising at the  implant  pierce point 
site or areas of anesthetic injections.    
For subjects in the Sham Control Group, the use of anesthetic and insertion of the cannula imparts the 
same risks except  for those directly attributable to an implant, without the potential benefit of the 
treatment.  
Spirox, Inc. 
LATERA RCT  Version 3.0 
23 March 2018  
  
 
LATERA RCT  Page 37 CONFIDENTIAL  8.2. Risk Mitigation  
The subject risks for participation in the  Lateral RCT Study are mitigated through device design, protocol 
development, and study conduct  methods.   
The Latera Implant is designed and indicated for use to support of the lateral nasal cartilages.  The device 
will be used as directed in the FDA Cleared Indications for Use.  The device has been commercially available in the US for over a year and used in three (3) clinical studies with consistent high efficacy and low complication rates, as described previously .   
The Latera RCT is a Group Sequential Study.  This is an adaptive study design that allows for interim 
data review for potentially halting enrollment for early demonstration of success or for futility (inability to reach the primary objectives).  Additionally, although the treatment assignment is blinded to the study subjects, an independent Data Monitoring Committee will be reviewing the data at pre -determined 
interim analyses to determine if the study is operationally sound or meets pre -determined success criteria, 
limiting randomization to no more subjects than are required to meet the primary objectives .   
Risk mitigation through s tudy operations include the select ion of experienced investigators wit h the 
appropriate research infrastructure, providing training and data monitoring to limit protocol deviations 
and operational execution.  The study includes IRB review and approval of the  study protocol, informed 
consents for appropriate risk disclosure, and the patient brochure and study poster to assure the study meets clinical research standards and regulatory requirements.      
The measures listed above will be implemented in this stud y to mitigate potential risks to the study 
subjects. 
8.3. Benefit to Subjects  
The Latera implant  has been successfully deployed in over 7,000 patients in the past year, including over 
300 in a research setting.  This has enabled a high proportion to have a reduction in nasal obstruction 
symptoms with a low complication rate.  This benefit may be afforded to the subjects that participate in 
this study. Subjects may also benefit from the additional monitoring and follow -up evaluations mandated 
by this study protoc ol.  The Sham Control subjects have the opportunity to cross -over, if these symptoms 
persist and they remain eligible for the Latera Implant in this study.  Those subjects will have the same 
potential benefit at that point as those randomized to the Latera  Implant arm.   
8.4. Study Justification  
Nasal valve collapse (NVC)  due to lateral wall weakness is significant contributor to NAO.  The Latera 
Implant offers a minimally invasive treatment to support the lateral cartilages .  The Latera RCT provides 
the opportu nity to rigorously assess the impact of the implant  itself in alleviating the symptoms of NVC  
due to lateral nasal wall weakness.   Patients with other primary contributors to NAO will not be included 
such as sept al conditions  or turbinate  hypertrophy since these potentially mask the full impact of the 
Latera Implant.   Three (3) prospective, single -arm studies have continued to  show the high rate of 
Spirox, Inc. 
LATERA RCT  Version 3.0 
23 March 2018  
  
 
LATERA RCT  Page 38 CONFIDENTIAL  reduction in nasal obstruction and low complications rates  as well as support the study design for 
super iority .  
9. ASSESSMENTS OF SAFETY 
9.1. Defining Adverse Events  
An adverse event is an untoward medical occurrence or exacerbation of an existing medical condition 
subsequent to the experimental therapy.  Adverse events are rated in several ways:  
•  Severity (mild, m oderate, severe)  
o Mild: No limitation of usual activities, no therapy or only symptomatic therapy required 
to treat the injury or illness.  
o Moderate : Some limitation of usual activities or specific therapy is required.  
o Severe: Inability to carry out usual activities, hospitalization, emergency treatment, life 
threatening events , or death.  
• Anticipated (anticipated, un anticipated)  
• Device and procedure relationships (unrelated, possibly related, definitely related, or relationshi p unknown)  
o Unrelated:  The clinical event is completely independent of study procedure/study 
device and/or evidence exists that the event is definitely related to another etiology.  
o Possibly related:  The clinical event occurs within a reasonable time sequence to study 
procedure/study device and there is some evidence to “possibly” suggest a causal relationship. However, the influence of other factors such as underlying disease, 
concomitant medications, or concurrent treatment may have contributed to the event . 
o Definitely related : The clinical event occurs in a plausible time relationship to study 
procedure/study device and cannot be explained by any concurrent disease or other 
devices, drugs or chemicals.  
o Relationship unknown : The relationship to the study procedure/study device is not 
known.  
Adverse events will be categorized as either serious or non -serious.  A Serious Adverse Event (SAE) is 
an event that meets at least one of the following:  
• Is fatal  
• Is life -threatening  
• Resul ts in persistent or significant disability/incapacity  
• Results in permanent impairment of a body function or permanent damage to a body structure  
• Results in hospitalization or prolongs a hospitalization  
• Necessitates medical or surgical intervention to precl ude permanent impairment of a body 
function or permanent damage to a body structure  
Spirox, Inc. 
LATERA RCT  Version 3.0 
23 March 2018  
  
 
LATERA RCT  Page 39 CONFIDENTIAL   An adverse device effect (ADE) is any unwanted and unintended response to a medical device. This 
definition includes any event resulting from insufficiencies or inadequacies in the instructions for use or the deployment of the device and any event that is a result of user error. A serious adverse device effect 
(SADE) is an adverse device effect that has resulted in any of the consequences characteristic of a serious 
adverse  event or that might have led to any of the consequences if suitable action had not been taken or 
intervention had not been made or if circumstances had been less opportune. An unanticipated adverse device effect (UADE) is defined as “any serious adverse e ffect on health or safety or any life -threatening 
problem or death caused by, or associated with, a device, if that effect, problem, or death was not 
previously identified in nature, severity, or degree of incidence in the investigational plan or application 
(including a supplementary application), or any other unanticipated serious problem associated with the device that relates to the rights, safety, or welfare of subjects.” 
Section 8.1  includes a list of possible adverse events associated with nasal interventions. These events 
are considered reportable at all time points throughout the trial and require submission to the Sponsor 
within 1 business day of receipt of information.  It is recognized that adverse event s may not be reported 
by the study subject until their follow up visits due to the low risk nature of the potential events.   
9.2. Reporting of Adverse Events  
In addition to events considered in the primary efficacy and primary safety analyses, all device - and/or 
procedure -related adverse events must be captured on the Adverse Event Case Report Form. The report 
should include, wherever possible, severity, duration, outcome, and the Investigator’s writ ten medical 
judgment as to the relationship of the adverse event to the study device, procedure, or underlying disease 
(i.e., not related, possibly related, definitely related, or relationship unknown).  
All SAEs must be reported to the Sponsor or its Cont ract Research Organization (CRO) within 1 business 
day of the Investigator’s knowledge of the event. The event is reported in the electronic data capture 
system. IRB notification of the adverse event may also be required, depending on the conditions of approval or requirements of the respective committee.  Any unanticipated adverse device effects must be 
reported to the Sponsor/CRO within 1 business day from when the Investigator first learns of it.   
Non-serious reportable adverse events are to be submitted via the electronic data capture system, also, 
within 1 business day  of learning about the event. Certain reportable events may require adjudication; 
therefore, supporting documentation must be sent to the Sponsor/CRO. 
9.3. Medical Monitor  
An independent Medic al Monitor, a member of  the Contract Research Organization, will be charged with 
evaluating all adverse events, device deficiencies (including user errors), device malfunctions, and other 
events that arise during the trial.  Each event will be assessed for  its relatedness to the procedure or to the 
device, classified as to its seriousness and whether it is an unanticipated adverse device effect. All adverse events will be MedDRA coded to the most recent MedDRA version at the time of the start of the trial. In 
the event of a conflict between the site and the Medical Monitor classifications, those of the Medical Monitor will prevail.  
Spirox, Inc. 
LATERA RCT  Version 3.0 
23 March 2018  
LATERA RCT  Page 40 CONFIDENTIAL  9.4. Data Monitoring Committee  
The Data Monitoring Committee  (DMC ) will be used in this study.  It is the responsibility of the DMC  
to assess safety -related issues by reviewing data in aggregate and to assess the results of the interim 
analyses for operational study execution and early assessment of superiority or futility. The DMC  for this 
trial will also assess efficacy with respect t o the group -sequential  design (§6.8 , page 34, above ). The 
DMC  membership is represented from the key medical disciplines involved with nasal interventions, and 
may include an external biostatistician. None of the members is directly involved in other aspects of the 
clinical trial. The Sponsor has contracted a Clinical Research Organization to organize, facilitate, and 
document meetings for the DMC  for this trial. The DMC  will meet regularly and as necessary, guided by 
a DMC  Charter.  
10.STUDY ADMINISTRATION
10.1. Site Initiation  and Study Monitoring
A Site Initiation Visit (SIV) will be conducted by the Sponsor or a designee, for example, its CRO,  to
ensure that all study supplies are present, to ensure proper training of the Investigator and study staffmembers in study -specific procedures, to ensure site readiness i s complete  prior to enrollment of the first
study subject at each  site.
Interim mo nitoring visits will be conducted by Spirox  Inc. personnel or a designee to ensure compliance
with the protocol, source data verification and other written instructions and regulatory guidelines.
10.2. Study Termination
Spirox Inc. and applicable regulatory authorities have the right to terminate the study or a particular study
site at any time. Situations that could warrant study termination include, but are not limited to:
a)Increased incidence of adverse experiences and/or the severity of such, suggestive of a potential,device- related health hazard
b)Insufficient subject enrollment
c)Recurrent protocol non -compliance, violations or deviations
d)Inaccurate, incomplete, and/or untimely data recording (>5 business days) on a recurrent basis
e)Lack of cooperation with monitoring visits (e.g., failure to adequately prepare for visits, address
action items from one visit to the next, or provide access to medical records)
10.3. Data Handling and Recordkeeping  
Completing, Signing and Archiving Case Repor t Forms  
The Investigator must keep a separate subject identification list showing enrollment numbers, names, and dates of birth to allow unambiguous identification of each subject included in the study.  It is 
Spirox, Inc. 
LATERA RCT  Version 3.0 
23 March 2018  
  
 
LATERA RCT  Page 41 CONFIDENTIAL  recommended a note be made in the medical reco rd that the subject is participating in a clinical research 
study. 
The required data will be recorded on the Case Report Forms (CRFs).  Clinical study data will be collected 
using electronic data capture ( EDC ). A web -based EDC  database will be used to reco rd and manage study 
data. CRF completion guidelines, the instructions for electronic data -entry, will be developed in 
conjunction with the sponsor, the CRO, and/or the EDC vendor.  An embedded audit trail will capture 
the date, time and user making updates  and changes to the electronic data.  
A mechanism in the EDC will allow the Investigator to approve the data electronically.  Additionally, 
study worksheets that become source documentation will require Investigator review and approval as 
indicated by signatures and dates.    
Because it is important to have proper data collection in a timely manner, within 5 business days, the 
Investigator/Study Coordinator shall complete the CRFs . When the monitor requests additional data or 
clarification of data for the CRF, the request should be answered satisfactorily before the next monitoring 
visit.  
Data Management and Archiving 
The Sponsor will be responsible for the processing and quality co ntrol of the data. Source data for safety 
will be retained for at least 2 years after the termination/completion of the study .  All other source data, 
eCRFs, copies of protocols and protocol amendments, device accountability forms, correspondence, 
subject identification lists, informed consent forms, and other essential documents must be retained for a 
period of at least 2 years after the final data lock.  
No study document or image will be destroyed without prior written agreement between the Sponsor and 
the Investigator.  Should the Investigator wish to assign the study records to another party or move them 
to another location, advance written notice must  be given to the Sponsor.  
11. ETHICS 
11.1. Informed Consent  
Written informed consent must be obtained for each su bject before any study -specific procedures or 
assessments are done and, specifically, prior to the subject being treated with the Latera implant .  The 
methods used in the Latera RCT will include an electronic informed consent (eIC) and traditional 
paper.  The Investigator or designee, trained on the protocol, will explain the nature, scope , anticipated 
benefits,  and potential risks involved in the study.  Written informed consent will be obtained after the 
aims, methods, anticipated benefits, and potential risks  are explained.  
All subjects may receive a stipend for their time and to cover travel costs for participation in the Latera 
RCT.  The stipend and schedule must be approved by the investigational site’s recognized IRB (central 
Spirox, Inc. 
LATERA RCT  Version 3.0 
23 March 2018  
LATERA RCT  Page 42 CONFIDENTIAL  IRB or local).  The plans for the study is as follows:  After complet ion the following study visits, subjects  
will receive a $50.00 prepaid debit card at end of the following visits: Baseline visit, Treatment, one (1) 
week,  one (1), three (3), and six (6) month; and they will receive a $100.00 prepaid debit card for  twelve 
(12), eighteen (18) and twenty- four (24) month study visits. The total compensation to each subject  will 
be $600.00 for completion of a ll of the study visits for the Latera Implant group of the study or it will be 
$750.00 for completion of  all the study visits for the Sham treatment group of t he study.  
If required by institutional policy, informed consent will be obtained prior to review of Baseline and Screening data. A Screening Consent Form may also be available to secure permission from the subject 
for reviewing prospective subject informat ion (if requested/required by site or IRB policy) prior to the 
subject agreeing to participate in the trial and signing the study -specific Informed Consent Form.  
Consenting addendums will be used to confirm continuing patient consent in the cases of re -implanting 
procedures and the cross -over implant procedures. 
The subject’s willingness to participate in the study will be documented in writing in a study -specific 
Informed Consent Form, which will be signed and dated by the subject or Legally Authorized 
Representative.  The Investigator will keep the original consent form and a copy will be given to the 
subject.  It will be explained to the subjects that they are free to refuse entry into the study and free to withdraw from the study at any time without prejudice to future treatment.  
11.2. Institutional Review Board (IRB)  
This study must be approved by an appropriate IRB at each study site  in accordance with  21 CFR Part 
56.  The Sponsor must receive a copy of the IRB approval letter (or equivalent documentation) for the study 
protocol and Informed Consent Form before the study can be started at that site or devices shipped to that Investigator.  The Sponsor will provide confirmation that sites may initiate consenting and enrollment 
after review of the approved IRB documents.   
The IRB and Sponsor must approve any significant changes or amendments to the protocol as well as a 
change of Principal Investigator.  Documentation of the IRB approval must be provided to the Sponsor. Records of all study review and approval  documents must be maintained by the Investigator in the 
Regulatory Binder and are subject to inspection by the Sponsor or regulatory authority during or after completion of the study.  Serious Adverse Events must also be reported to the IRB , as per their reporting 
requirements , and Sponsor (reference Section 10 for reporting instructions).  
The Investigator must notify the IRB, as per their reporting guidelines, and the Sponsor when he or she deviates from the protocol.  The Sponsor must be notified of all  relevant action taken by the IRB and 
must receive a copy of all study -related correspondence between the Investigator and the IRB.  
Spirox, Inc. 
LATERA RCT  Version 3.0 
23 March 2018  
LATERA RCT  Page 43 CONFIDENTIAL  The IRB must  receive notification of the completion of the study and final report within 3 months of 
study completion or termination. A copy of these reports must be provided to the Sponsor. The 
Investigator must maintain an accurate and complete record of all submissions made to the IRB , including 
a list of all reports and documents submitted .     
12. INVESTIGATORS AND RESPONSIBILITIES
12.1. Participating Institutions and Investigators
Study sites and Investigators will be selected based on a variety of factors including, but not limited to,experience with clinical research trials, proficiency  with nasal interventional techniques  including Latera
Implant experience, access to required facilities and equipment, sufficient and adequately trained clinical
and research personnel, and availability of potential subjects.
12.2. Agreement s
All Principal Investigators and their Sub -Investigators or Co -Investigators must sign an Investigator
Agreement.  Spirox must receive a copy of the signed Investigator Agreements before the study may be
started at that institution .  Any Investigators joining the study after the site has been initiated may not
receive devices or participate until study training occurs and is documented and an agreement is signed
and received by the Sponsor.
12.3. Investigator Responsibilities
Investigator responsibilities include, but are not limited to, the following:
a.) Conducting the study  in accordance with this investigational plan, signed agreement , and 
applicable regulations protecting the rights and safety of study subjects  
b.) Informing all subjects that the study design includes randomization and has a sham control arm, 
and ens uring that  the requirements relating to obtaining informed consent and IRB approval are 
met 
c.) Ensuring that informed consent is obtained for each study subject in accordance with applicable regulations (e.g., ISO 14155 -1, 21 CFR Part 50)  
d.) Ensuring that IRB approval is secured prior to starting the study and ensuring continuing review 
and approval as required throughout the investigation 
e.) Ensuring all associates, colleagues, and employees assisting in the conduct of the study are informed about their obligations, are adequately qualified and trained, and meet their commitments  
f.) Maintaining adequate and accurate records and ensuring those records are available for inspection at any time  
g.) Ensuring that conducting the study does not give rise to conflict of interest (financial disclosure 
is required)   
h.) Controlling of any study devices at their institution  
Spirox, Inc. 
LATERA RCT  Version 3.0 
23 March 2018  
LATERA RCT  Page 44 CONFIDENTIAL  13. DATA SECURITY AND SCIENTIFIC INTEGRITY
13.1.  Access to Data  
The Sponsor, auditors, and health authority inspectors (or their agents) will be given access to source data 
and document ation (e. g., medical charts/records, laboratory test results, printouts, videotapes, etc.) for 
source data verification, provided that subject confidentiality is maintained in accordance with local requirements. 
The Investigator must maintain, at all times, the primary records (source document ations ) of each 
subject’s data. Examples of source documents are hospital records, office visit records, examining 
physician’s finding or notes, consultant’s written opinion or notes, laboratory reports, device inventory, device label records, and CRFs that are used as the source (source worksheets) . 
The Investigator will maintain a confidential subject identification list that allows the unambiguous 
identification of each subject. All study -related documents must  be ke pt until notification by Spirox, Inc.  
at the study closeout visit.  
13.2.  Security and Confidentiality 
Each  Investigator must ensure that the privacy of all subjects, including their personal identity and all 
personal medical information, will be maintained at all times. In CRFs and other documents or image 
material submitted to the Sponsor, subjects will not be identified by their names, but by an identification 
code (i.e., subject number ).  If identifying information is transferred to the Sponsor, the Sponsor will de -
identify or anonymize  the information to the extent possible.  Information will be maintained in a secure 
manner.  
Personal medical information may be reviewed to verifying data  recorded in the CRFs. The monitor may 
perform source data verification on behalf of the Sponsor or regulatory authorities. Personal medical 
information will always be treated as confidential.  
Electronic data will only be accessible to authorized personnel  using a unique user identifier and 
password. Access to electronic study data will be provided to research personnel upon completion of training. Read and write access will be provided to investigational sites but only for information and subject data at t heir own site. The CRO will have read -only access and can post queries for potent ial data -
related discrepancies.  
14. PUBLICATIONS
Latera RCT will be registered in the ClinicalTrials.gov website by Spirox, as the  study sponsor.  Spirox is 
committed to complying  with applicable regulatory requirements for study registration and is committed 
to supporting dissemination of study results, as described in the protocol (protocol derived outcomes), in peer-reviewed medical journals, regardless of outcome.  
Spirox, Inc. 
LATERA RCT  Version 3.0 
23 March 2018  
LATERA RCT  Page 45 CONFIDENTIAL  At the comple tion of the primary analyses, it is anticipated that the Principal Investigators will prepare 
and submit a multi-center manuscript for publication in a reputable scientific journal.  Additional 
authorship will be based on contribution to the conduct of the study and the target journal requirements.  
Further analyses, beyond those presented in the initial multi -center publication may be proposed to the 
Sponsor for s econdary manuscripts and abstracts.  Investigators are encouraged to submit requests to the 
sponsor for data sets to support further investigations.  The Sponsor will respond in a timely manner for 
the data sets and reviews for publications .   
Before submission for publication or presentation of data from the Latera RCT, the author(s) will provide 
them to Spirox at least 30 days in ahead of submission or deadline.  Spirox reserves the right to review 
and comment on draft abstracts, manuscripts, presentations and other communications by investigators 
regarding Spirox-sponsor ed clinical studies , prior  to their submission or public disclosure, to protect 
intellectual property and confidential information.  
15. ABBREVIATIONS
Abbreviations contained throughout this document are listed in  Table 4, below . 
Table 4. Abbreviations 
AE Adverse Event  
ADE  Adverse Device Effect  
ASC  Ambulatory Surgery Center  
CFR Code of Federal Regulations  
CMP  Clinical Monitoring Plan  
CRF Case Report Form – Paper or electronic 
CRO  Contract Research Organization  
EDC  Electronic Data Capture 
ESS Epworth Sleepiness Scale 
FDA  Food and Drug Administration 
GCP  Good Clinical Practice, including ICH E6  
GMP  Good Manufacturing Practices 
HIPAA Health Insurance Portability and Accountability Act 
ICH Internatio nal Conference on Harmonisation 
ICMJE  International Committee of Medical Journal Editors  
ICF Informed Consent Form  
IFU Instructions for Use 
Spirox, Inc. 
LATERA RCT  Version 3.0 
23 March 2018  
LATERA RCT  Page 46 CONFIDENTIAL  IRB Investigational Review Board  
ISO International Organization for Standardization  
LWI Lateral Wall Insufficiency 
MedDRA Medical Dictionary for Regulatory Activities  
NAO  Nasal Airway Obstruction  
NSR  Non-significant Risk  
NOSE  Nasal Obstruction Symptom Evaluation Instrument  
NVC  Nasal Valve Collapse 
OSA  Obstructive Sleep Apnea  
PRO  Patient Reported Outcome  
PI Principal Investigator  
QA Quality Assurance  
QC Quality Control  
QOL  Quality of Life  
QSR  21CFR Part 820, Quality System Regulation  
SAE Serious Adverse Event  
SADE  Serious Adverse Device Effect  
SAP Statistical Analysis Plan  
SOP Standard Operating Procedure  
UADE  Unanticipated Adverse Device Effect  
US United States  
VAS  Visual Analog Scale 
Spirox, Inc. 
LATERA RCT  Version 3.0 
23 March 2018  
LATERA RCT  Page 47 CONFIDENTIAL  16. REFERENCES
1. Mink PJ. Physiologie der Obern Luftwege. Leipzig. Germany.: Vogel; 1920.
2.Becker SS, Dobratz EJ, Stowell N, Barker D, Park SS. Revision septoplasty: review of sources
of persistent nasal obstruction. Am J Rhinol 2008;22:440-4.3. Most SP. Trends in functional rhinoplasty. Arch Facial Plast Surg 2008;10:410-3.4.Most SP. Comparing Methods for Repair of the External Valve: One More Step Toward a
Unified View of Lateral Wall Insufficiency. JAMA Facial Plast Surg 2015;17:345-6.5.Stewar t MG, Smith TL, Weaver EM, et al. Outcomes after nasal septoplasty: results from the
Nasal Obstruction Septoplasty Effectiveness (NOSE) study. Otolaryngol Head Neck Surg
2004;130:283-90.
6. Lavinsky- Wolff M, Camargo HL, Jr., Barone CR, et al. Effect of turbinate surgery in
rhinoseptoplasty on quality-of- life and acoustic rhinometry outcomes: a randomized clinical trial.
Laryngoscope 2013;123:82-9.7.Sufyan A, Ziebarth M, Crousore N, Berguson T, Kokoska MS. Nasal batten grafts: are patients
satisfied? Arch Facial Plast Surg 2012;14:14-9.
8. Murrell GL. Auricular cartilage grafts and nasal surgery. Laryngoscope 2004;114:2092-102.9.Cochran CS, Ducic Y, DeFatta RJ. Restorative rhinoplasty in the aging patient. Laryngoscope
2007;117:803-7.10.Islam A, Arslan N, Felek SA, Celik H, Demirci M, Oguz H. Reconstruction of the internal
nasal valve: modified splay graft technique with endonasal approach. Laryngoscope
2008;118:1739-43.
11.Toriumi DM, Josen J, Weinberger M, Tardy ME, Jr. Use of alar batten grafts for correction of
nasal valve collapse. Arch Otolaryngol Head Neck Surg 1997;123:802-8.12.Akcam T, Friedman O, Cook TA. The effect on snoring of structural nasal valve dilatation
with a butterfly graft. Arch Otolaryngol Head Neck Surg 2004;130:1313- 8.
13.Winkler AA, Soler ZM, Leong PL, Murphy A, Wang TD, Cook TA. Complications associated
with alloplastic implants in rhinoplasty. Arch Facial Plast Surg 2012;14:437-41.
Spirox, Inc. 
LATERA RCT  Version 3.0 
23 March 2018  
  
 
LATERA RCT  Page 48 CONFIDENTIAL  14. Ramakrishnan JB, Danner CJ, Yee SW. The use of porous polyethylene implants to correct 
nasal valve collapse. Otolaryngol Head Neck Surg 2007;136:357-61. 
15. Rhee JS, Sullivan CD, Frank DO, Kimbell JS, Garcia GJ. A systematic review of patient -
reported nasal obstruction scores: defining normative and symptomatic ranges in surgical patients. 
JAM A Facial Plast Surg 2014;16:219-25; quiz 32. 
16. Khosh MM, Jen A, Honrado C, Pearlman SJ. Nasal valve reconstruction: experience in 53 consecutive patients. Arch Facial Plast Surg 2004;6:167-71. 
17. Stewart MG, Witsell DL, Smith TL, Weaver EM, Yueh B, Hannley MT. Development and 
validation of the Nasal Obstruction Symptom Evaluation (NOSE) scale. Otolaryngol Head Neck Surg 2004;130:157-63. 
18. Landes CA, Ballon A, Roth C. In- patient versus in vitro degradation of P(L/DL)LA and PLGA. 
J Biomed Mater Res B App l Biomater 2006;76:403-11. 
19. Tsao GJ, Fijalkowski N, Most SP. Validation of a grading system for lateral nasal wall 
insufficiency. Allergy Rhinol (Providence) 2013;4:e66-8. 
20. Fisher LD, Dixon DO, Herson J, Frankowski RK, Hearon MS, Pearce KE. Intention to treat in 
clincial trials. In: Pearce KE, ed. Statistical issues in drug research and development. New York: 
Marcel Dekker; 1990:331-50. 
  
Spirox, Inc. 
LATERA RCT  Version 3.0 
23 March 2018  
  
 
LATERA RCT   Page 50 CONFIDENTIAL  ATTACHMENT B.  DECLARATION OF HELSINKI 
 
WORLD MEDICAL ASSOCIATION DECLARATION OF HELSINKI  
 
Adopted by the 18th World Medical Assembly, Helsinki, Finland, June 1964. Amended by the 29th 
World Medical Assembly, Tokyo, Japan, October 1975; 35th World Medical Assembly, Venice, Italy, 
October 1983; and the 41st World Medical Assembly, Hong Kong, September 1989. 
 
 0. Introduction 
I. Basic Principles  
II. Medical Research Combined with Clinical Care (Clinical Research)  
III. Non -Therapeutic Biomedical Research Involving Human Subjects (Non- Clinical Biomedical 
Research)  
 
Introduction  
It is the mission of the physician to safeguard the health of the people. His or her knowledge and conscience 
are dedicated to the fulfillment of this mission.  
The Declaration of Geneva of the World Medical Assembly binds the physician with the words, "The health 
of my patient will be my first consideration," and the International Code of Medical Ethics declares that, 
"A physician shall act only in the patient's interest when providing medical care, which might have the effect of weakening the physical and mental condi tion of the patient." 
The purpose of biomedical research involving human subjects must be to improve diagnostic, therapeutic and prophylactic procedures, and the understanding of the aetiology and pathogenesis of disease. 
In current medical practice, most diagnostic, therapeutic or prophylactic procedures involve hazards. This 
applies especially to biomedical research.  
Medical progress is based on research, which ultimately must rest in part on experimentation involving 
human subjects. 
In the field of biomedical research, a fundamental distinction must be recognized between medical research, 
in which the aim is essentially diagnostic or therapeutic for a patient, and medical research, the essential 
object of which is purely scientific and without implying direct diagnostic or therapeutic value to the person subjected to the research.  
Special caution must be exercised in the conduct of research, which may affect the environment, and the 
welfare of animals used for research must be respected.  
Spirox, Inc. 
LATERA RCT  Version 3.0 
23 March 2018  
  
 
LATERA RCT   Page 51 CONFIDENTIAL  Because it is essential that the results of laboratory experiments be applied to human beings to further 
scientific knowledge and to help suffering humanity, the World Medical Association has prepared the 
following recommendations as a guide to every physician in biome dical research involving human subjects. 
They should be kept under review in the future. It must be stressed that, the standards, as drafted, are only a guide to physicians all over the world. Physicians are not relieved from criminal, civil and ethical responsibilities under the laws of their own countries. 
I. Basic Principles  
 
1. Biomedical research involving human subjects must conform to generally accepted scientific principles, 
and should be based on adequately performed laboratory and animal experimentation, and on a thorough 
knowledge of the scientific literature.  
2. The design and performance of each experimental procedure involving human subjects should be clearly 
formulated in an experimental protocol, which should be transmitted for consideration, comment and 
guidance to a specially appointed committee independent of the investigator and the sponsor, provided that this independent committee is in conformity with the laws and regulations of the country, in which the 
research experiment is performed.  
3. Biomedical research involving human subjects should be conducted only by scientifically qualified 
persons, and under the supervision of a clinically competent medical person. The responsibility for the human subject must always rest with a medically qu alified person, and never rest on the subject of the 
research, even though the subject has given his or her consent.  
4. Biomedical research involving human subjects cannot legitimately be carried out, unless the importance of the objective is in proportion to the inherent risk to the subject.  
5. Every biomedical research project involving human subjects should be preceded by careful assessment of predictable risks, in comparison with foreseeable benefits to the subject or to others. Concern for the 
interests of the subject must always prevail over the interests of science and society.  
6. The right of the research subject to safeguard his or her integrity must always be respected. Every 
precaution should be taken to respect the privacy of the subject, and to minimize the impact of the study on 
the subject's physical and mental integrity, and on the personality of the subject. 
7. Physicians should abstain from engaging in research projects involving human subjects, unless they are 
satisfied that the hazards involved are believed to be predictable. Physicians should cease any investigation, 
if the hazards are found to outweigh the potential benefits. 
8. In publication of the results of his or her research, the physician is obliged to preserve the accuracy of 
the results. Reports of experimentation, not in accordance with the principles laid down in this Declaration, 
should not be accepted for publication. 
Spirox, Inc. 
LATERA RCT  Version 3.0 
23 March 2018  
  
 
LATERA RCT   Page 52 CONFIDENTIAL  9. In any research on human beings, each potential subject must be adequately informed of the aims, 
methods, anticipated benefits and potential hazards of the study, and the discomfort it may entail. He or she should be informed that he or she is at liberty to abstain from participation in the study, and that he or she 
is free to withdraw his or her consent to par ticipation at any time. The physician should then obtain the 
subject's freely -given informed consent, preferably in writing. 
10. When obtaining informed consent for the research project, the physician should be particularly cautious, 
if the subject is in a  dependent relationship to him or her, or may consent under duress. In that case, the 
informed consent should be obtained by a physician, who is not engaged in the investigation, and who is 
completely independent of this official relationship. 
11. In case of legal incompetence, informed consent should be obtained from the legal guardian in 
accordance with national legislation. Where physical or mental incapacity makes it impossible to obtain informed consent, or when the subject is a minor, permission from the responsible relative replaces that of 
the subject, in accordance with national legislation. Whenever the minor child is in fact able to give a 
consent, the minor's consent must be obtained in addition to the consent of the minor's legal guardian. 
12. T he research protocol should always contain a statement of the ethical considerations involved, and 
should indicate that the principles enunciated in the present Declaration are complied with. 
 
II. Medical Research Combined with Clinical Care (Clinical Research)  
 
1. In the treatment of the sick person, the physician must be free to use a new diagnostic and therapeutic 
measure, if, in his or her judgment, it offers hope of saving life, reestablishing health, or alleviating suffering.  
2. The potential benefits , hazards and discomfort of a new method should be weighed against the advantages 
of the best current diagnostic and therapeutic methods. 
3. In any medical study, every patient --including those of a control group, if any--  should be assured of the 
best proven diagnostic and therapeutic method.  
4. The refusal of the patient to participate in a study must never interfere with the physician- patient 
relationship. 
5. If the physician considers it essential not to obtain informed consent, the specific reasons for this proposal 
should be stated in the experimental protocol for transmission to the independent committee (I.2). 
6. The physician can combine medical research with professional care, the objective being the acquisition 
of new medical knowledge, only to t he extent that medical research is justified by its potential diagnostic 
or therapeutic value for the patient.  
Spirox, Inc. 
LATERA RCT  Version 3.0 
23 March 2018  
  
 
LATERA RCT   Page 53 CONFIDENTIAL  III. Non -Therapeutic Biomedical Research Involving Human Subjects (Non -Clinical Biomedical 
Research)  
1. In the purely scientific application of medical research carried out on a human being, it is the duty of the 
physician to remain the protector of the life and health of that person, on whom biomedical research is 
being carried out. 
2. The subjects should be volunteers --either healthy persons, o r patients for whom the experimental design 
is not related to the patient's illness.  
3. The investigator or the investigating team should discontinue the research, if in his/her or their judgment 
it may, if continued, be harmful to the individual.  
4. In re search on man, the interest of science and society should never take precedence over considerations 
related to the well-being of the subject.  
Spirox, Inc. 
LATERA RCT  Version 3.0 
23 March 2018  
  
 
LATERA RCT   Page 54 CONFIDENTIAL  ATTACHMENT C.  INFORMED CONSENT FORM 
  
Spirox, Inc. 
LATERA RCT  Version 3.0 
23 March 2018  
  
 
LATERA RCT   Page 55 CONFIDENTIAL  ATTACHMENT D.  LATERA INSTRUCTIONS FOR U SE 
  
Spirox, Inc. 
LATERA RCT  Version 3.0 
23 March 2018  
  
 
LATERA RCT   Page 56 CONFIDENTIAL  ATTACHMENT E.  FINANCIAL DISCLOSURE FORM 
  
Spirox, Inc. 
LATERA RCT  Version 3.0 
23 March 2018  
  
 
LATERA RCT   Page 57 CONFIDENTIAL  ATTACHMENT F.  CASE REPORT FORMS AND PATIENT REPORTED 
OUTCOMES 
  
Spirox, Inc. 
LATERA RCT  Version 3.0 
23 March 2018  
  
 
LATERA RCT   Page 58 CONFIDENTIAL  ATTACHMENT G. PATIENT AND SITE BROCHURE 